BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 872 filers reported holding BAXTER INTL INC in Q2 2016. The put-call ratio across all filers is 0.49 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $226 | -100.0% | 4,959 | -92.6% | 0.05% | -95.9% |
Q1 2022 | $5,197,000 | +278.8% | 67,021 | +319.2% | 1.13% | +260.0% |
Q4 2021 | $1,372,000 | -13.1% | 15,986 | -18.5% | 0.32% | -31.8% |
Q2 2021 | $1,578,000 | +147.3% | 19,606 | +164.7% | 0.46% | +96.6% |
Q2 2020 | $638,000 | -96.9% | 7,407 | -97.2% | 0.24% | -68.5% |
Q3 2018 | $20,423,000 | +15.9% | 264,920 | -2.3% | 0.75% | +11.8% |
Q1 2018 | $17,627,000 | -11.0% | 271,025 | -14.1% | 0.67% | -9.4% |
Q3 2017 | $19,799,000 | +81.8% | 315,528 | +75.4% | 0.74% | +80.2% |
Q2 2017 | $10,889,000 | +517.6% | 179,863 | +429.2% | 0.41% | +510.4% |
Q1 2017 | $1,763,000 | -93.1% | 33,989 | -94.1% | 0.07% | -93.5% |
Q4 2016 | $25,430,000 | +105.5% | 573,515 | +120.6% | 1.04% | +101.2% |
Q3 2016 | $12,373,000 | +30.2% | 259,937 | +23.7% | 0.52% | +35.9% |
Q2 2016 | $9,500,000 | +288.9% | 210,079 | +182.5% | 0.38% | +238.4% |
Q3 2015 | $2,443,000 | -62.6% | 74,355 | -22.0% | 0.11% | -51.9% |
Q1 2015 | $6,533,000 | -81.6% | 95,366 | -80.6% | 0.23% | -75.6% |
Q2 2014 | $35,566,000 | +43.7% | 491,924 | +30.6% | 0.95% | +30.7% |
Q3 2013 | $24,750,000 | +131.4% | 376,774 | +144.0% | 0.73% | +104.5% |
Q2 2013 | $10,695,000 | – | 154,402 | – | 0.36% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tavio Capital LLC | 68,405 | $5,890,000 | 7.81% |
Iron Triangle Partners LP | 330,000 | $28,413,000 | 7.16% |
Veritas Asset Management LLP | 8,942,428 | $769,943,000 | 5.64% |
TSFG, LLC | 93,405 | $8,042,000 | 5.31% |
GENERATION INVESTMENT MANAGEMENT LLP | 10,606,094 | $913,185,000 | 5.27% |
Third Point | 4,000,000 | $344,400,000 | 4.72% |
Avidity Partners Management LP | 800,900 | $68,957,000 | 4.42% |
Palmer Knight Co | 62,275 | $5,362,000 | 4.17% |
Eos Focused Equity Management, L.P. | 36,786 | $3,167,000 | 3.70% |
Dundas Partners LLP | 196,133 | $16,887,000 | 3.69% |